Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

Journal of Psychiatric Research

Volumn 39, Issue 1, 2005, Pages 43-53

  Brannan, Stephen K ^a   Mallinckrodt, Craig H ^b   Brown, Eileen B ^b   Wohlreich, Madelaine M ^b   Watkin, John G ^b   Schatzberg, Alan F ^c  

^a Cyberonics Inc   (Italy)

^b ELI LILLY AND COMPANY   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Depression; Duloxetine; Norepinephrine; Pain; Physical symptoms; Serotonin

Indexed keywords

DULOXETINE; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; APPETITE DISORDER; ARTICLE; BACKACHE; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROLITHIASIS; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECORDING; SCORING SYSTEM; SEDATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT WITHDRAWAL; VISUAL ANALOG SCALE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 7044229576     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2004.04.011     Document Type: Article

References (66)

1. Adly C., Straumanis J., Chesson A. Fluoxetine prophylaxis of migraine. Headache. 32:1992;101-104
2. American Psychiatric Association: Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994
3. Anderson I.M., Tomenson B.M. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J. Psychopharmacol. 8:1994;238-249
4. Anderson I.M., Tomenson B.M. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ. 310:1995;1433-1438
5. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harv. Rev. Psychiatry. 7:2000;257-277
6. Arnold L.M., Hess E.V., Hudson J.I., et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am. J. Med. 112:2002;191-197
7. Bair M.J., Robinson R.L., Eckert G.J., et al. Impact of pain on depression treatment response in primary care. Psychosom. Med. 66:2004;17-22
8. Bialik R.J., Ravindran A.V., Bakish D., et al. A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J. Psychiatry Neurosci. 20:1995;265-270
9. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G., et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 25:2001;871-880
10. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group. Psychopharmacology (Berl) 1986;90:131-8
11. Cleeland C.S. Measurement of pain by subjective report. Chapman C.R., Loeser J.D. Advances in pain research and therapy. Issues in pain measurement. vol. 12:1989;391-403 Raven Press, New York, NY
12. Cleeland C.S., Ryan K.M. Pain assessment: global use of the Brief Pain Inventory. Ann. Acad. Med. Singapore. 23:1994;129-138
13. Collins S.L., Moore R.A., McQuay H.J., et al. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J. Pain Symptom. Manage. 20:2000;449-458
14. DeLoach L.J., Higgins M.S., Caplan A.B., et al. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth. Analg. 86:1998;102-106
15. Detke M.J., Lu Y., Goldstein D.J., et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry. 63:2002;308-315
16. Detke M.J., Lu Y., Goldstein D.J., et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J. Psychiatr. Res. 36:2002;383-390
17. Dickens C., Jayson M., Sutton C., et al. The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain. Psychosomatics. 41:2000;490-499
18. Fava M. Somatic symptoms, depression, and antidepressant treatment. J. Clin. Psychiatry. 63:2002;305-307
19. Fava M., Mallinckrodt C.H., Detke M.J., et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J. Clin. Psychiatry. 65:2004;521-530
20. Fields H.L., Heinricher M.M., Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu. Rev. Neurosci. 14:1991;219-245
21. Fishbain D.A., Cutler R., Rosomoff H.L., et al. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: A structured review. Pain Medicine. 1:2000;310-316
22. Gerber P.D., Barrett J., Barrett J., et al. Recognition of depression by internists in primary care: a comparison of internist and gold standard psychiatric assessments. J. Gen. Intern. Med. 4:1989;7-13
23. Goldstein D.J., Mallinckrodt C., Lu Y., et al. Duloxetine in the treatment of major depressive disorder: a double- blind clinical trial. J. Clin. Psychiatry. 63:2002;225-231
24. Goldstein DJ, Lu Y, Iyengar S, Lee TC, Detke MJ, Duloxetine in the treatment of the pain associated with diabetic neuropathy. Presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA; May 19th 2003
25. Goodnick P.J. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann. Clin. Psychiatry. 13:2001;31-41
26. Greden J.F. The burden of recurrent depression: causes, consequences, and future prospects. J. Clin. Psychiatry. 62(Suppl 22):2001;5-9
27. Guy W. ECDEU assessment manual for psychopharmacology, revised 1976. 1976;National Institutes of Mental Health, Rockville, MD
28. Hameroff S.R., Cork R.C., Scherer K., et al. Doxepin effects on chronic pain, depression and plasma opioids. J. Clin. Psychiatry. 43:1982;22-27
29. Hameroff S.R., Weiss J.L., Lerman J.C., et al. Doxepin's effects on chronic pain and depression: a controlled study. J. Clin. Psychiatry. 45:1984;47-53
30. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62
31. Jones S.L. Descending noradrenergic influences on pain. Prog. Brain Res. 88:1991;381-394
32. Kellner R. A symptom questionnaire. J. Clin. Psychiatry. 48:1987;268-274
33. Khan A., Khan S.R., Walens G., et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology. 28:2003;552-557
34. Kroenke K., Spitzer R.L., Williams J.B., et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch. Fam. Med. 3:1994;774-779
35. Leon A.C. Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. J. Clin. Psychiatry. 62(Suppl 4):2001;12-16
36. Lindsay P.G., Olsen R.B. Maprotiline in pain-depression. J. Clin. Psychiatry. 46:1985;226-228
37. Lynch M.E. Antidepressants as analgesics: a review of randomized controlled trials. J. Psychiatry Neurosci. 26:2001;30-36
38. Mallinckrodt C.H., Clark W.S., David S.R. Accounting for dropout bias using mixed-effects models. J. Biopharm. Stat. 11:2001;9-21
39. Mallinckrodt C.H., Clark W.S., David S.R. Type I error rates from mixed effects model repeated measures versus fixed effects ANOVA with missing values imputed via Last Observation Carried Forward. Drug Informat. J. 35:2001;1215-1225
40. McQuay H.J., Tramer M., Nye B.A., et al. A systematic review of antidepressants in neuropathic pain. Pain. 68:1996;217-227
41. Nelson J.C., Mazure C.M., Bowers M.B. Jr., et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry. 48:1991;303-307
42. Nemeroff C.B., Schatzberg A.F., Goldstein D.J., et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol. Bull. 36:2002;106-132
43. Ohayon M.M., Schatzberg A.F. Using chronic pain to predict depressive morbidity in the general population. Arch. Gen. Psychiatry. 60:2003;39-47
44. O'Malley P.G., Jackson J.L., Santoro J., et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J. Fam. Pract. 48:1999;980-990
45. Onghena P., De Cuyper H., Van Houdenhove B., et al. Mianserin and chronic pain: a double-blind placebo-controlled process and outcome study. Acta Psychiatr. Scand. 88:1993;198-204
46. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord 1990;18:289-99
47. Posse M., Hallstrom T. Depressive disorders among somatizing patients in primary health care. Acta Psychiatr. Scand. 98:1998;187-192
48. Rakel R.E. Depression. Prim. Care. 26:1999;211-224
49. Raskin J., Goldstein D.J., Mallinckrodt C.H., et al. Duloxetine in the long-term treatment of major depressive disorder. J. Clin. Psychiatry. 64:2003;1237-1244
50. Richardson B.P. Serotonin and nociception. Ann. N.Y. Acad. Sci. 600:1990;511-519
51. Salerno S.M., Browning R., Jackson J.L. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch. Intern. Med. 162:2002;19-24
52. Shaw J., Creed F. The cost of somatization. J. Psychosom. Res. 35:1991;307-312
53. Sheehan D.V., Lecrubier Y., Sheehan K.H., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 59(Suppl 20):1998;22-33
54. Simon G.E., Von Korff M., Piccinelli M., et al. An international study of the relation between somatic symptoms and depression. N. Engl. J. Med. 341:1999;1329-1335
55. Stahl S.M. Does depression hurt. J. Clin. Psychiatry. 63:2002;273-274
56. Steffens D.C., Krishnan K.R., Helms M.J. Are SSRIs better than TCAs. Comparison of SSRIs and TCAs: a meta- analysis. Depress Anxiety. 6:1997;10-18
57. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry. 178:2001;234-241
58. Thompson W.L., Brunelle R.L., Enas G.G., et al. Routine laboratory tests in clinical trials. 1990;Eli Lilly and Company, Indianapolis, IN. pp. 1-63 (data on file)
59. Von Korff M., Simon G. The relationship between pain and depression. Br. J. Psychiatry Suppl. 1996;101-108
60. Vrethem M., Boivie J., Arnqvist H., et al. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin. J. Pain. 13:1997;313-323
61. Ward N.G. Tricyclic antidepressants for chronic low-back pain. Mechanisms of action and predictors of response. Spine. 11:1986;661-665
62. Ward N.G., Bloom V.L., Friedel R.O. The effectiveness of tricyclic antidepressants in the treatment of coexisting pain and depression. Pain. 7:1979;331-341
63. Ward N.G., Bloom V.L., Dworkin S., et al. Psychobiological markers in coexisting pain and depression: toward a unified theory. J. Clin. Psychiatry. 43:1982;32-41
64. Ward N.G., Bloom V.L., Fawcett J., et al. Urinary 3-methoxy-4- hydroxyphenethylene glycol in the prediction of pain and depression relief with doxepin: preliminary findings. J. Nerv. Ment. Dis. 171:1983;55-58
65. Ward N., Bokan J.A., Phillips M., et al. Antidepressants in concomitant chronic back pain and depression: doxepin and desipramine compared. J. Clin. Psychiatry. 45:1984;54-59
66. Wells K.B., Stewart A., Hays R.D., et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 262:1989;914-919